Ocean Biomedical's oncology segment is dedicated to the discovery and development of innovative therapies for various cancer types, including non-small cell lung cancer and glioblastoma multiforme. This segment focuses on developing antibody therapeutic product candidates inhibiting Chi3l1, as well as bi-specific antibody product candidates inhibiting Chi3l1 plus PD-1 and CTLA-4. Research and development efforts are geared towards enhancing tumor cell cytotoxicity and improving patient outcomes. The company is actively pursuing preclinical studies and plans to engage with the FDA to advance these therapies into clinical trials. This segment aims to address unmet medical needs in cancer treatment through targeted immunotherapies and novel therapeutic approaches.

The fibrosis therapeutics segment at Ocean Biomedical is focused on developing treatments for fibrotic diseases, particularly Idiopathic Pulmonary Fibrosis (IPF) and Hermansky-Pudlak Syndrome. The company is developing a small molecule product candidate targeting Chit1 to address these conditions. Research activities involve identifying and validating novel targets, conducting preclinical studies, and optimizing drug candidates for efficacy and safety. The goal is to provide effective therapeutic options for patients suffering from debilitating fibrotic diseases, improving their quality of life and overall prognosis. This segment leverages advanced molecular biology and biochemistry techniques to develop targeted therapies with minimal side effects.

Ocean Biomedical's infectious disease segment is dedicated to combating malaria through the development of innovative vaccines and therapeutics. This segment utilizes the WPDS platform to create a malaria vaccine candidate, a humanized mAb malaria therapeutic candidate targeting Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic candidate targeting PfGARP. Research and development efforts are focused on understanding the mechanisms of malaria infection, identifying effective targets, and developing novel interventions to prevent and treat the disease. The company aims to contribute to global efforts to eradicate malaria by providing accessible and effective solutions.